Low molecular weight 35 kDa hyaluronan fragment HA35 in the treatment of bone metastasis pain: A case report

Author:

Zhang Zongchun1,Jia Xiaoxiao2,Treger Dylan3,Hui Mizhou24ORCID

Affiliation:

1. Department of Radiotherapy, Qingdao Cancer Hospital, Qingdao, China

2. Department of anesthesiology, Hynaut Laboratories, Hynaut Group, Qingdao, China

3. DeWitt Daughtry Family Department of Surgery, Miller School of Medicine, University of Miami, Miami, FL

4. Pharmaceutical Manufacture Department, Nakhia Impex Pharmaceutical Co., Ltd., Ulaanbaatar, Mongolia.

Abstract

Rationale: Late-stage cancer patients often experience severe pain due to bone metastasis, caused by structural damage and cancer-induced inflammation. Hyaluronan, known to alleviate pain by blocking the TRVP1 calcium channel, faces limitations due to its high molecular weight. However, 35 kDa low molecular weight hyaluronan fragment (HA35) have shown promise in relieving various pains, including cancer-related pain. Nonetheless, evidence regarding their efficacy in bone metastasis pain remains scarce. Patients concerns: A 52-year-old female with a rectal malignant tumor and multiple secondary tumors in the sacrum and lungs, accompanied by bone metastasis pain. Despite undergoing radiotherapy, her pain relief was unsatisfactory. Before treatment with HA35, her numerical rating scale score was 10, severely affecting her sleep, appetite, and daily activities. Diagnoses: The patient was diagnosed with rectal malignant tumor with multiple metastases, presenting symptoms such as sacral metastasis pain, anal pain, lower limb pain, and anterior abdominal pain. Sacral metastasis pain and lower limb pain indicated a clear diagnosis of bone metastasis pain. Interventions: Treatment involved subcutaneous injection into the deep fat tissue layer of the abdomen. A subcutaneous injection of 100 mg/5 mL of HA35 was administered once into the deep fat tissue of the abdomen, with subsequent injections repeated every 3 days. Outcomes: Following 1 injection, the patient’s pain score decreased to 6 points within 20 minutes, providing 40% pain relief. After 40 minutes, the score further dropped to 4 points, with 60% pain relief. After 50 injections, pain was consistently controlled at around 3 points. Lessons subsections: Subcutaneous injection of HA35 into the abdominal fat tissue effectively alleviates pain in cancer and bone metastasis patients resistant to conventional treatments. Additionally, it helps alleviate anxiety and fatigue, and improves diet and sleep, thereby offering crucial palliative care for advanced cancer patients.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference17 articles.

1. Pain management in metastatic bone disease: a literature review.;Ahmad;Cureus,2018

2. Recent advances in the treatment of bone metastases and primary bone tumors: an up-to-date review.;Bădilă;Cancers (Basel),2021

3. Use of corticosteroids for pain control in cancer patients with bone metastases: a comprehensive literature review.;Lim;Curr Opin Support Palliat Care,2017

4. Corticosteroids: review of the history, the effectiveness, and adverse effects in the treatment of joint pain.;Stone;Pain Physician,2021

5. Opioids and chronic pain: an analytic review of the clinical evidence.;Nadeau;Front Pain Res (Lausanne),2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3